---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-078617"
form_type: "8-K"
ticker: "IPSC"
cik: "0001850119"
company_name: "Century Therapeutics, Inc."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:26:20.330827+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Century Therapeutics Q2 net loss $32.5M; cash runway into Q4 2027; CEO named Board Chair

## Summary
- Net loss of $32.5M for Q2 2025 (vs. $31.2M in Q2 2024); cash & equivalents $158.5M as of June 30.
- Cash runway extended into Q4 2027 after workforce reduction completed July 2025.
- CEO Brent Pfeiffenberger appointed Board Chair; Joseph Jimenez steps down, becomes special advisor.
- CNTY-101 CALiPSO-1 trial dosing two patients; clinical data expected by year-end 2025.
- CNTY-308 enters IND-enabling studies; clinical start planned in 2026.

## SEC filing metadata
- accession: 0001104659-25-078617
- form_type: 8-K
- ticker: IPSC
- cik: 0001850119
- company_name: Century Therapeutics, Inc.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850119/000110465925078617/0001104659-25-078617-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850119/000110465925078617/tm2523439d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-078617
- JSON: https://secwatch.observer/filing/0001104659-25-078617.json
- Plain text: https://secwatch.observer/filing/0001104659-25-078617.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.